SGRYSurgery Partners, Inc.
Is the price fair?
Undemanding: modest expectations priced in and cheap vs its sector.
Priced for a decline (~−3% a year). The price demands less than its three-year revenue growth of 8% a year, expectations look modest.
Sector median 22.6× across 130 covered peers. EV/EBIT counts debt as part of the price, so a cash-rich and a borrowed company can be compared on the same footing.
All from derived, as of Jun 30, 2026.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What SGRY's price assumes
Today's price asks for −2.6% free cash flow growth a year; over the last three years Surgery Partners, Inc. delivered 37%, less than the record.
Price / sales · no P/E: the last twelve months did not end in a profit
- Free cash flow yield
- 9.3%
Free cash flow yield · Medical Care Facilities median 7.1%
- Growth the price implies
- −2.6%
Growth the price implies · The price pays for −2.6% free cash flow growth a year for a decade; the business has delivered +37% a year over the last three.
- Price / book
- 1.21
Price / book · today's price, trailing year to Jun 30, 2026
Details›
- Price / booktoday's price, trailing year to Jun 30, 2026
- 1.21
- EV / EBITtoday's price, trailing year to Jun 30, 2026
- 14.5
- EV / salestoday's price, trailing year to Jun 30, 2026
- 1.65
- Free cash flow, trailing twelve months
- $188M
- Market capitalisation
- $2.02B
- 3-year revenue growth
- +8.2%
- 3-year free cash flow growth
- +37%
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.